These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28381801)

  • 1. Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients.
    Watanabe A; Yamamoto K; Ioroi T; Hirata S; Harada K; Miyake H; Fujisawa M; Nakagawa T; Yano I; Hirai M
    Biol Pharm Bull; 2017; 40(4):458-464. PubMed ID: 28381801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
    Kim HR; Park HS; Kwon WS; Lee JH; Tanigawara Y; Lim SM; Kim HS; Shin SJ; Ahn JB; Rha SY
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):825-35. PubMed ID: 24013576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
    Chu YH; Li H; Tan HS; Koh V; Lai J; Phyo WM; Choudhury Y; Kanesvaran R; Chau NM; Toh CK; Ng QS; Tan PH; Chowbay B; Tan MH
    PLoS One; 2015; 10(8):e0134102. PubMed ID: 26244574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.
    Low SK; Fukunaga K; Takahashi A; Matsuda K; Hongo F; Nakanishi H; Kitamura H; Inoue T; Kato Y; Tomita Y; Fukasawa S; Tanaka T; Nishimura K; Uemura H; Hara I; Fujisawa M; Matsuyama H; Hashine K; Tatsugami K; Enokida H; Kubo M; Miki T; Mushiroda T
    PLoS One; 2016; 11(2):e0148177. PubMed ID: 26914831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
    Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
    Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.
    Miura Y; Imamura CK; Fukunaga K; Katsuyama Y; Suyama K; Okaneya T; Mushiroda T; Ando Y; Takano T; Tanigawara Y
    BMC Cancer; 2014 Dec; 14():964. PubMed ID: 25515134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
    Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
    Beuselinck B; Lambrechts D; Van Brussel T; Wolter P; Cardinaels N; Joniau S; Lerut E; Karadimou A; Couchy G; Sebe P; Ravaud A; Zerbib M; Caty A; Paridaens R; Schöffski P; Verkarre V; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
    Acta Oncol; 2014 Oct; 53(10):1413-22. PubMed ID: 24874929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.
    Teo YL; Wee HL; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
    Pharmacogenomics J; 2016 Feb; 16(1):47-53. PubMed ID: 25778465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.
    Numakura K; Tsuchiya N; Kagaya H; Takahashi M; Tsuruta H; Inoue T; Narita S; Huang M; Satoh S; Niioka T; Miura M; Habuchi T
    Anticancer Drugs; 2017 Jan; 28(1):97-103. PubMed ID: 27564227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.
    Werbrouck E; Bastin J; Lambrechts D; Verbiest A; Van Brussel T; Lerut E; Machiels JP; Verschaeve V; Richard V; Debruyne PR; Decallonne B; Schöffski P; Bechter O; Wolter P; Beuselinck B
    Acta Clin Belg; 2019 Jun; 74(3):180-188. PubMed ID: 29792121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients.
    Yamamoto K; Shinomiya K; Ioroi T; Hirata S; Harada K; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Bito T; Nishigori C; Miyake H; Fujisawa M; Hirai M
    Target Oncol; 2016 Feb; 11(1):93-9. PubMed ID: 26300443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population.
    Yamamoto K; Ioroi T; Kanaya K; Shinomiya K; Komoto S; Hirata S; Harada K; Watanabe A; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Miyake H; Fujisawa M; Hirai M
    Med Oncol; 2016 Mar; 33(3):24. PubMed ID: 26833481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
    Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.
    Chae JW; Teo YL; Ho HK; Lee J; Back HM; Yun HY; Karlsson MO; Kwon KI; Chan A
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):623-32. PubMed ID: 27485537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer.
    Ghafouri H; Ghaderi B; Amini S; Nikkhoo B; Abdi M; Hoseini A
    Tumour Biol; 2016 Jun; 37(6):7901-6. PubMed ID: 26700668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of
    Tanda M; Yamamoto K; Hori T; Nishiguchi H; Yagi M; Shimizu M; Konishi T; Ozaki T; Yoshioka N; Tachihara M; Ito T; Ikushima S; Omura T; Yano I
    Anticancer Res; 2023 Apr; 43(4):1775-1783. PubMed ID: 36974789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
    Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
    Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the
    Tan Y; Cao K; Ren G; Qin Z; Zhao D; Li N; Chen X; Xia Y; Lu Y
    Xenobiotica; 2020 Feb; 50(2):237-243. PubMed ID: 31021303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.